JP2024535867A5 - - Google Patents

Info

Publication number
JP2024535867A5
JP2024535867A5 JP2024517040A JP2024517040A JP2024535867A5 JP 2024535867 A5 JP2024535867 A5 JP 2024535867A5 JP 2024517040 A JP2024517040 A JP 2024517040A JP 2024517040 A JP2024517040 A JP 2024517040A JP 2024535867 A5 JP2024535867 A5 JP 2024535867A5
Authority
JP
Japan
Prior art keywords
amino
ethyl
alkyl
cancer
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024517040A
Other languages
English (en)
Japanese (ja)
Other versions
JP7883791B2 (ja
JP2024535867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/042431 external-priority patent/WO2023043630A1/en
Publication of JP2024535867A publication Critical patent/JP2024535867A/ja
Publication of JP2024535867A5 publication Critical patent/JP2024535867A5/ja
Application granted granted Critical
Publication of JP7883791B2 publication Critical patent/JP7883791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024517040A 2021-09-16 2022-09-02 治療薬としてn-アリールピリミジン-2-アミン誘導体を有する化合物 Active JP7883791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163244775P 2021-09-16 2021-09-16
US63/244,775 2021-09-16
PCT/US2022/042431 WO2023043630A1 (en) 2021-09-16 2022-09-02 Compounds having n-arylpyrimidin-2-amine derivatives as therapeutic agents

Publications (3)

Publication Number Publication Date
JP2024535867A JP2024535867A (ja) 2024-10-02
JP2024535867A5 true JP2024535867A5 (cg-RX-API-DMAC7.html) 2025-06-23
JP7883791B2 JP7883791B2 (ja) 2026-07-02

Family

ID=85603404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517040A Active JP7883791B2 (ja) 2021-09-16 2022-09-02 治療薬としてn-アリールピリミジン-2-アミン誘導体を有する化合物

Country Status (4)

Country Link
US (1) US20240270699A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401735A4 (cg-RX-API-DMAC7.html)
JP (1) JP7883791B2 (cg-RX-API-DMAC7.html)
WO (1) WO2023043630A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023138612A1 (en) * 2022-01-19 2023-07-27 Silexon Ai Technology Co., Ltd. Heterocyclic compounds useful as hpk1 inhibitors
EP4727941A1 (en) * 2023-06-15 2026-04-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373226T3 (es) * 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CA2723205C (en) * 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
WO2010090875A1 (en) * 2009-01-21 2010-08-12 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
WO2010129802A1 (en) * 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
EP3670500A4 (en) * 2017-08-18 2020-12-16 Beijing Hanmi Pharmaceutical Co., Ltd. CHEMICAL COMPOUND, PHARMACEUTICAL COMPOSITION OF IT, CORRESPONDING USE AND APPLICATION
WO2019090198A1 (en) * 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US20230416225A1 (en) * 2020-11-09 2023-12-28 Merck Sharp & Dohme Llc Diaminopyrimidine carboxamide inhibitors of hpk1
CN121851009A (zh) * 2021-01-22 2026-04-14 苏州信诺维医药科技股份有限公司 Hpk1抑制剂、其制备方法、药物组合物及其应用
WO2022253252A1 (en) * 2021-06-03 2022-12-08 Silexon Biotech Co., Ltd. Heterocyclic compounds useful as hpk1 inhibitors

Similar Documents

Publication Publication Date Title
TWI770113B (zh) 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺
RU2310651C2 (ru) Азотсодержащие ароматические производные, фармацевтическая композиция, их содержащая, способ лечения и применение
JP2022520448A5 (cg-RX-API-DMAC7.html)
CN109863140B (zh) 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
CN103097375B (zh) Ccr2的环己基-氮杂环丁烷拮抗剂
CN114206848A (zh) 作为整合应激通路的调节剂的被取代的环烷基化合物
TW201927756A (zh) 整合應激路徑之調節劑
CN1639153A (zh) 吲哚基马来酰亚胺衍生物
JP4324791B2 (ja) 2−アシルアミノチアゾール誘導体又はその塩
JP2014139226A5 (cg-RX-API-DMAC7.html)
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
JP2017531679A (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
JP2023541522A (ja) 低分子量タンパク質分解物質及びその適用
JP2015531773A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2016515096A (ja) スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
KR20170066650A (ko) Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
JP2017505762A5 (cg-RX-API-DMAC7.html)
CN102725283A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN107108554B (zh) 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑
EP3324954A1 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
JP2024539633A5 (cg-RX-API-DMAC7.html)
WO2019034153A1 (zh) 一种化合物,其药物组合物及其用途及应用
JP6184866B2 (ja) 新規抗がん剤
AU2015233559A1 (en) Inhibitors of the Wnt signalling pathways
JP2024508817A (ja) B型肝炎ウイルス感染症の処置および予防のためのベンゾチアゾリルビシクロ[1.1.1]ペンタン誘導体